Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Stocks Battled to a Mixed Finish Tuesday As Drugmakers Rally

By Marley Jay, AP Markets Writer | January 31, 2017

The facade of the New York Stock Exchange. (Credit: AP Photo/Richard Drew)

U.S. stocks fought their way to a mixed finish Tuesday as drugmakers rallied, which mostly canceled out losses for industrial companies. Investors shifted their money to less risky investments for the second day in a row.

For the second straight day, stocks started with substantial losses. Industrial companies, which have climbed lately, fell the most as UPS tumbled after a weak fourth-quarter report. Banks also slipped.

Investors bid up assets that are traditionally seen as less risky, including gold, government bonds, and stocks that pay big dividends. Drug companies also rallied after President Donald Trump met with industry executives and discussed ideas including faster drug approvals and lower taxes.

Jim Paulsen, chief investment strategist for Wells Capital Management, said investors are looking for safer investments because the change from Barack Obama’s administration to Donald Trump’s has created so many changes in government.

“More than anything right now, it’s just the pace of news,” he said. “It is so dramatic.”

The stock market made huge gains after Trump was elected last fall, and Paulsen said it’s not a surprise that investors would sell some of their holdings, take some profits, and move to lower-risk investments at some point.

The Dow Jones industrial average sank 107.04 points, or 0.5 percent, to 19,864.09 as companies like Goldman Sachs and Boeing returned some of their recent gains.

The S&P 500 lost 2.03 points, or 0.1 percent, to 2,278.87. It fell as much as 13 points early on. The S&P 500 has fallen for four days in a row. While that is its longest losing streak since before the presidential election, the losses have been small.

The Nasdaq composite gained 1.07 points to 5,614.79. The Russell 2000 index of small-company stocks rose 9.49 points, or 0.7 percent, to 1,361.82. On the New York Stock Exchange, more stocks rose than fell.

Athletic apparel maker Under Armour plunged after investors were disappointed with its fourth-quarter report, which included higher expenses. Under Armour also issued a weak full-year forecast and said its chief financial officer is leaving. The stock tumbled $7.45, or 25.7 percent, to $21.49. It dropped 30 percent last year and is now trading at its lowest price in two years.

United Parcel Service sank after the package delivery company forecast an annual profit that was far smaller than analysts expected. UPS expects to earn no more than $6.10 a share this year while FactSet says experts expected $6.15 per share. UPS gave up $7.90, or 6.8 percent, to $109.13 and FedEx fell $4.14, or 2.1 percent, to $189.11. That helped pull industrial companies lower.

Drug companies jumped after Trump said he wants less regulation on prescription drugs because that could speed up drug approvals. While Trump again said he wants to reduce drug prices, investors seemed pleased with proposals that could reduce drugmakers’ costs and boost their profits, as well as with the tone of the meeting.

Just three weeks ago Trump said drugmakers were “getting away with murder” on prices.

The Nasdaq Biotech index climbed 2.8 percent. Companies that make both generic and name-brand drugs traded higher, as did prescription drug distributors.

After the market closed, Apple reported a bigger profit and greater sales than analysts expected as iPhone sales bounced back from a recent slump. The tech giant’s stock rose 2.6 percent in after-hours trading.

Bond prices rose. The yield on the 10-year Treasury note fell to 2.46 percent from 2.49 percent. That hurt financial stocks, as lower bond yields reduce interest rates and the profits banks make from lending.

Investors who want income also bought stocks that pay outsize dividends, including real estate investment trusts and utility companies. Shopping mall operators Simon Property Group and GGP both traded higher after their quarterly reports. Simon gained $6.03, or 3.4 percent, to $183.77 and GGP rose 88 cents, or 3.7 percent, to $24.84.

The price of gold and silver made their biggest jumps in two weeks. Gold rose $15.40, or 1.3 percent, to $1,211.40 an ounce. Silver gained 39 cents, or 2.3 percent, to $17.54 an ounce. Copper picked up 7 cents, or 2.7 percent, to $2.73 a pound. That was its largest move in three weeks.

Another day of protests against parts of Trump’s agenda and challenges for some of his cabinet nominees who haven’t been confirmed by Congress made investors a bit more nervous early in the day. The VIX, an index known as Wall Street’s “fear gauge,” jumped 9 percent around midday, but finished only 1 percent higher. It had climbed Monday.

U.S. crude oil rose 18 cents to $52.81 a barrel in New York. Brent crude, the benchmark for international oil prices, added 47 cents to $55.70 a barrel in London. However energy companies continued to decline. After big gains over the last year, especially in November and early December, energy companies have done worse than the rest of the market. Exxon Mobil lost 97 cents, or 1.1 percent, to $83.89.

Natural gas companies fell as the price of that fuel fell 12 cents, or 3.6 percent, to $3.12 per 1,000 cubic feet. In other energy trading, wholesale gasoline rose 2 cents to $1.53 a gallon. Heating oil picked up 1 cent to $1.61 a gallon.

The dollar fell to 112.76 yen from 113.67 yen. The euro rose to $1.0803 from $1.0695.

Germany’s DAX lost 1.3 percent and the CAC 40 of France fell 0.7 percent. The FTSE 100 index in Britain lost 0.3 percent. Japan’s benchmark Nikkei 225 dipped 1.7 percent. The South Korean Kospi lost 0.8 percent. Markets in Hong Kong, China and Taiwan were closed for Lunar New Year holidays.

(Source: Associated Press)


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE